HC Wainwright reaffirmed their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a research note published on Thursday morning, Benzinga reports. HC Wainwright currently has a $3.00 price objective on the stock. TransCode Therapeutics Stock Performance RNAZ stock opened at $1.15 on Thursday. The stock’s 50 day moving average price is […]